Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell

Key Points

• Wall Street Zen downgraded Enliven Therapeutics (NASDAQ:ELVN) from a "hold" to a "sell," although the broker consensus remains a "Moderate Buy" (five Buys, one Sell) with a $43.40 average price target.
• Shares opened at $41.70 with a market cap of about $2.54 billion, and the company reported a quarterly loss of ($0.48) per share—missing estimates—with analysts forecasting roughly -1.7 EPS for the year.
• Insiders have been net sellers recently: the CFO sold 10,000 shares and insiders offloaded 16,230 shares over the past 90 days, even though insiders still own about 25.9% of the stock.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Sunday.

Several other research firms have also recently weighed in on ELVN. Weiss Ratings restated a "sell (d-)" rating on shares of Enliven Therapeutics in a report on Monday, April 20th. HC Wainwright boosted their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a report on Thursday, March 26th. Finally, Mizuho boosted their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an "outperform" rating in a report on Wednesday, March 25th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $43.40.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $41.70 on Friday. The company has a market cap of $2.54 billion, a price-to-earnings ratio of -22.42 and a beta of 0.32. The firm has a 50 day simple moving average of $36.23 and a 200 day simple moving average of $26.87. Enliven Therapeutics has a one year low of $14.78 and a one year high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). As a group, analysts expect that Enliven Therapeutics will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 10,000 shares of the business's stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the sale, the chief financial officer owned 51,000 shares of the company's stock, valued at $1,508,580. The trade was a 16.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard A. Heyman sold 1,230 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the completion of the sale, the director directly owned 22,647 shares in the company, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 16,230 shares of company stock valued at $473,201. Company insiders own 25.90% of the company's stock.

Institutional Trading of Enliven Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ELVN. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock valued at $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets raised its position in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $83,000. Quantbot Technologies LP raised its position in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $95,000. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.